Investigational drug · Phase 2
MS-553
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "MS-553"
First trial start
2026
Jul 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MS-553", any sponsor or status.
Conditions studied
As listed on its trial records.
- CLL (Chronic Lymphocytic Leukemia)
- SLL (Small Lymphocytic Lymphoma)
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "MS-553" as an intervention, largest first.
MingSight Pharmaceuticals, IncIndustry
NCT03492125 · 60 participants · Start May 25, 2018 · Primary completion Nov 28, 2023
Drug: MS-553; MS-553 and 4 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Aggressive Lymphoma
Sites: Ann Arbor, Michigan; New York, New York; Columbus, Ohio · 5 sites in all
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.Industry
NCT04187443 · 45 participants (planned) · Start Jun 2, 2020 · Primary completion Oct 30, 2026
Drug: MS-553 · For: Diabetic Macular Edema; Macular Edema; Type 2 Diabetes With Diabetic Macular Edema and 2 more
Sites: Changsha, China; Chengdu, China; Shanghai, China
MingSight Pharmaceuticals Pty LimitedIndustry
NCT02406989 · 32 participants · Start Apr 2015 · Primary completion Aug 2015
Drug: MS-553; Placebo · For: Safety and PK in Healthy Volunteers
Sites: Melbourne, Australia
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.Industry
NCT05272813 · 13 participants · Start Apr 28, 2022 · Primary completion Nov 28, 2023
Drug: MS-553 · For: Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Beijing, China
- A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLLNot yet recruiting
MingSight Pharmaceuticals, IncIndustry
NCT06979076 · 12 participants (planned) · Start Jul 2026 · Primary completion Sep 2028
Drug: MS-553, DS1; MS-553, DS2 · For: CLL (Chronic Lymphocytic Leukemia); SLL (Small Lymphocytic Lymphoma)
MingSight Pharmaceuticals, IncIndustry
NCT05720052 · 8 participants · Start Feb 6, 2023 · Primary completion Nov 28, 2023
Drug: MS-553 · For: Relapsed or Refractory B-cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma (FL) and 4 more
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKCβ.
Jebaraj BMC, Stilgenbauer S · Blood Cancer Discov 2026
- PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia.
Gordon BK, Muhowski EM, Singh J, et al. · Blood Cancer Discov 2026
Also in development for CLL (Chronic Lymphocytic Leukemia)
- RocbrutinibLP-168, NWP-775Phase 36 trials
Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.